CLEC-2 Inhibitors
CLEC-2 inhibitors are chemical compounds designed to specifically target and block the function of CLEC-2, a C-type lectin-like receptor expressed on the surface of platelets and certain immune cells. CLEC-2 plays a crucial role in various biological processes, particularly in hemostasis, immune regulation, and the maintenance of vascular integrity. This receptor is known to recognize and bind to podoplanin, a glycoprotein expressed on the surface of certain cells, including lymphatic endothelial cells and some types of tumor cells. The interaction between CLEC-2 and podoplanin triggers signaling pathways that influence platelet aggregation and immune cell responses. Inhibitors of CLEC-2 disrupt this interaction, blocking the receptor's ability to engage in these signaling processes, thus preventing the downstream effects associated with CLEC-2 activation.
The mechanism by which CLEC-2 inhibitors function can involve binding to the receptor's extracellular domain, preventing podoplanin or other ligands from interacting with CLEC-2. Alternatively, inhibitors might block the intracellular signaling domains of CLEC-2, thereby disrupting signal transduction following receptor activation. Since CLEC-2 plays a critical role in platelet function and the modulation of immune cell activity, its inhibition provides a valuable tool for studying these processes. By blocking CLEC-2, researchers can explore the receptor's role in maintaining vascular integrity, regulating immune responses, and facilitating cellular communication in both normal and pathological states. CLEC-2 inhibitors are important for understanding the molecular mechanisms behind platelet activation and immune signaling, shedding light on how these pathways contribute to broader physiological processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A may downregulate CLEC-2 by inhibiting histone deacetylase, leading to a tightly wound chromatin structure that restricts access of transcription machinery to the CLEC-2 gene. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine could decrease CLEC-2 expression through DNA demethylation, thereby reducing the binding affinity of transcriptional repressors to the CLEC-2 gene promoter. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 could downregulate CLEC-2 by competitively binding to the BET bromodomain, displacing transcriptional regulators that are essential for the initiation of CLEC-2 transcription. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 may reduce CLEC-2 expression by inhibiting the PI3K pathway, resulting in decreased activity of downstream transcription factors that stimulate CLEC-2 gene expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 might decrease CLEC-2 expression by inhibiting the MEK1/2 enzymes, leading to reduced ERK pathway signaling and subsequent downregulation of transcription factors essential for CLEC-2 transcription. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 could decrease CLEC-2 expression by inhibiting the JNK pathway, leading to lower activity of AP-1 transcription factor, which may be necessary for CLEC-2 gene expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 may decrease expression of CLEC-2 by inhibiting p38 MAP kinase activity, resulting in diminished activation of transcription factors that drive CLEC-2 gene expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 could inhibit CLEC-2 expression by selectively blocking MEK1/2 enzymes, thereby reducing the phosphorylation and activation of ERK1/2 and ultimately lowering CLEC-2 gene expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin may reduce CLEC-2 levels by inhibiting PI3K, which is crucial for activating AKT signaling and may result in decreased transcriptional activity of CLEC-2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin could inhibit CLEC-2 expression by binding to mTOR and subsequently lowering the activity of S6K1 and 4E-BP1, which are involved in the translation initiation of the CLEC-2 mRNA. | ||||||